2024-10-07 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences is a biopharmaceutical company that develops, manufactures, and markets medications for the treatment of various infectious diseases, including HIV, hepatitis, and COVID-19.

**1. Performance Comparison:**

* **Cumulative return:** GILD: -12.26%, VOO (S&P 500): 133.14%
* **Performance Gap:** -145.4 (Relative gap: 6.43%) - GILD has significantly underperformed the S&P 500 over the period considered. 
    * Note: The relative gap is measured as a percentage of the maximum and minimum gap observed historically, with 100 representing the most extreme underperformance and 0 representing the most extreme outperformance. 

**2. Recent Price Movement:**

* **Closing Price:** $84.59
* **5-Day Moving Average:** $84.26
* **20-Day Moving Average:** $83.22
* **60-Day Moving Average:** $77.96
* **Analysis:** The price is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a potential upward trend in the short to medium term.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 59.2 - This suggests that the stock is neither overbought nor oversold.
* **PPO (Percentage Price Oscillator):** -0.24 -  This indicates a slightly bearish sentiment in the market.
* **Delta_Previous_Relative_Divergence:** -4.28 (Negative) - This suggests a potential short-term bearish trend.
* **Expected Return:** 0.0% -  This indicates that the stock is not expected to outperform the S&P 500 in the next 5 years, based on historical data and current market conditions. 

**4. Recent Earnings and Outlook:**

| Date      | EPS     | Revenue      |
|-----------|---------|--------------|
| 2024-08-08 | 1.29    | $6.95B       |
| 2024-05-08 | -3.34   | $6.69B       |
| 2023-11-07 | 1.75    | $7.05B       |
| 2023-08-04 | 0.84    | $6.60B       |
| 2024-08-08 | 0.84    | $6.60B       |

**Analysis:** Gilead's most recent earnings report for the quarter ended August 8, 2024, showed an EPS of $1.29, exceeding analyst expectations by $0.19. The revenue of $6.95 billion also surpassed analysts' estimates. This positive performance suggests a potential turnaround in the company's business. However, further analysis is required to assess the sustainability of this trend.

**5. News and Recent Issues:**

* **Recent Market Outlook:**  The market outlook for Gilead is currently mixed, with analysts remaining cautious due to the company's dependence on a few key drugs and potential competition.
* **Analyst Opinions:** Some analysts remain optimistic about Gilead's long-term potential, citing its strong cash flow and efforts to develop new therapies. However, others remain cautious, citing the company's high debt levels and potential regulatory challenges.
* **Performance Highlights:**  Gilead has recently performed well in the market, driven by the success of its HIV and hepatitis C treatments. However, the company's COVID-19 treatment has been a source of concern, as it faces increasing competition.

**6. Summary and Analysis:**

Gilead Sciences currently faces a mixed outlook. While recent earnings reports indicate a positive turnaround in the company's business, the long-term performance remains uncertain due to its dependence on a few key drugs and potential competition. The stock's recent performance has been positive, but it is important to consider the technical indicators and analyst opinions before making any investment decisions.

**7. Recommendations:**

* **Investors with a long-term perspective and a high risk tolerance might consider investing in Gilead.** 
* **It is important to monitor the company's earnings reports and the overall market sentiment before making any investment decisions.**
* **Seeking advice from a qualified financial advisor is always recommended before making any investment decisions.**
